Dr Nicholas Marston, Brigham and Women’s Hospital, Boston, USA, considers the major milestones reached by novel triglyceride lowering agents in 2025 and looks ahead at clinical trials that are expected to report exciting new data during 2026.
Professor Robert Rosenson (Icahn School of Medicine at Mount Sinai, New York, USA) examines the evidence linking triglycerides to metabolic fatty liver disease and presents clinical trial data supporting the potential of novel triglyceride-lowering agents in future management of patients diagnosed with this difficult-to-treat condition.
Professor Chris J Packard, Professor of Vascular Biochemistry, Glasgow, discusses clinical trial results for eicosapentaenoic acid (EPA) in lowering TG levels and considers which patients may benefit in terms of reduced risk of atherosclerotic cardiovascular disease.
Dr Eliot Brinton, Utah Lipid Center, Salt Lake City, USA discusses the evidence of using Evinacumab in children with Homozygous familial hypercholesterolaemia.
Professor Daniel Gaudet, University of Montreal, Canada discusses what the results from the SHASTA-2 trial mean for clinicians
Professor Gary Lewis, Director of the Banting and Best Diabetes Centre at the University of Toronto, Canada, and co-author of the report discusses the evidence presented in this important publication and its implications for clinicians and patients.
